GIỚI THIỆU VỀ TẬP NÀY
In this episode of Communicable, Emily McDonald and Josh Davis host Henning Bundgaard and Sami El-Dalati for a discussion on early oral antibiotic switch for endocarditis, focusing on the POET trial, led by Bundgaard, and its clinical impact seven years after the results were first published in 2019 [1]. The episode also covers the ‘prose’ and cons of early oral switch therapy, as well as broader challenges of implementing new evidence in practice when it goes against long-standing dogma.
References
- Iversen K, et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis, NEJM 2018. DOI: 10.1056/NEJMoa1808312
Further reading:
- Pries-Heje MM, et al. Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial, NEJM 2022. DOI: 10.1056/NEJMc2114046
- El-Dalati S, et al. Partial Oral Versus Intravenous Antibiotic Therapy for Endocarditis With Management by a Multidisciplinary Team: A Retrospective Cohort Study, OFID 2025. DOI: 10.1093/ofid/ofaf625
- McDonald EM, et al. Guidelines for Diagnosis and Management of Infective Endocarditis in Adults: A WikiGuidelines Group Consensus Statement, JAMA Netw Open 2023. DOI: 10.1001/jamanetworkopen.2023.26366
- European Society of Cardiology (ESC). 2023 ESC Guidelines for the management of endocarditis, 2023.
Tiếng Anh
Hoa Kỳ
TRONG PHÂN ĐOẠN NÀY
BẢN CHÉP ÂM THANH 🔗
Communicable E62: POET
===
[00:00:00]
Emily: Hello, everyone, and welcome back to Communicable, the podcast brought to you by CMI Communications, ESCMID's open access journal covering infectious diseases and clinical microbiology. I am Emily McDonald. I'm a physician in general internal medicine, infectious disease trialist and scientist at McGill University in Montreal, Canada, and associate editor at CMI Communications.
So, the POET trial, partial oral intravenous, antibiotic treatment of …
===
[00:00:00]
Emily: Hello, everyone, and welcome back to Communicable, the podcast brought to you by CMI Communications, ESCMID's open access journal covering infectious diseases and clinical microbiology. I am Emily McDonald. I'm a physician in general internal medicine, infectious disease trialist and scientist at McGill University in Montreal, Canada, and associate editor at CMI Communications.
So, the POET trial, partial oral intravenous, antibiotic treatment of …
TÌM KIẾM CÁC TẬP TRƯỚC
Tìm kiếm các tập trước của Communicable.
Tuyên bố miễn trừ trách nhiệm: Podcast và tác phẩm nghệ thuật được nhúng trên trang này là của CMI Communications, là tài sản của chủ sở hữu và không được liên kết hoặc xác nhận bởi Listen Notes, Inc.
CHỈNH SỬA
Cảm ơn bạn đã giúp cơ sở dữ liệu podcast luôn cập nhật.